EXECUTIVE INTERVIEWS

• Frank Gupton – Revolutionizing Pharma Manufacturing From The Outside In

  “I’ve gotten more press during the last six and a half months than in my 68 years on this earth,” jokes Frank Gupton, Ph.D., a professor at Virginia Commonwealth University who has been involved in some key recent developments in pharma manufacturing.

• How A First-Time Pharma CEO Faces Hypergrowth

  Jeffrey Nau, Ph.D., discusses the career path that led him to becoming president and CEO of Oyster Point Pharma, a publicly traded biopharma now valued at more than $550 million and on the brink of commercial launch. 

• AI And Machine Learning Prepare Pharma For The Data Onslaught

  When I reached out to several clinical executives in my network for their thoughts on trends that will impact trials in the coming year, the two mentioned most frequently were AI and decentralized trials.

• From “Musty Towel” To “Golden Age:” Biosimilars In 2021 And Beyond

  The industry has certainly come a long way since the “great doubt” of 2019. However, I’d argue the biosimilar space still remains on the verge of transformation.

• View From The Inside: What’s Shaping Biopharma In 2021 And Beyond?

  How the pandemic will continue to disrupt and why smart money is on AI for improving drug discovery and development.

• Can Your CDMO Relationships Survive Another “Virtual” Year?

  Lori Hoffman, head of alliance management, Slayback Pharma; and Greg Birrer, quality head, Elusys Therapeutics, talk about how the pandemic has affected CDMOs.

• What Do 10 Biopharma Finance Experts Expect for 2021?

  We invited 10 biopharmaceutical industry finance experts to provide their perspectives on everything from remote work, to supply chains, to the reshoring of U.S. biopharmaceutical manufacturing operations.

• The Future Of Biopharma Manufacturing Has Never Been More Critical

  Here’s what six biopharmaceutical manufacturing executives have to say on emerging manufacturing innovations, key trends to pay attention to in 2021 (and beyond), and so much more.

• Politics and the Pandemic — Where Are They Taking Biopharma? Industry CEOs Speak Out

  Seventeen top executives of companies representing the entrepreneurial edge of biopharma innovation provide feedback on how the COVID-19 pandemic and the politics surrounding it could affect their companies’ futures and the industry.

• COVID-19 And Cell And Gene Sector: Contingency Planning For 2021 And Beyond

  Some of the brightest luminaries representing the sector’s various subsets all answer the same question: As a result of COVID-19, how have you and your team had to pivot to ensure continued success in 2021 and beyond?

• Reflection And Projection — 15 CEOs Map Biopharma’s Present And Future

  2020 was the year that everything changed, including this year’s annual CEO outlook article. Normally fully focused on the future, this year’s version contains some reflection, which seems appropriate in our new norm.

• Pets, Perseverance, And Manufacturing Facility Bring Biotech Success

  Patricia Lawman, cofounder and CEO of the biotech firm Morphogenesis, explains the company’s unlikely genesis and different approach to animal testing.

• The Making Of A Pharma CEO

  The story of how Paula Ragan, Ph.D., went from aspiring academic to biopharmaceutical protégé to CEO of X4 Pharmaceuticals, a six-year-old company focused on improving the immune system for treating rare diseases.

• David Lucchino’s Circuitous Route To CEO Of Frequency Therapeutics

  Biopharma CEO wasn’t David Lucchino’s first, second, or even third choice as a career path. Today, though, he uses elements of his diverse background to lead his second pharma startup, Frequency Therapeutics.